e-Edition
Obituaries
Special Sections
Special Occasions
Contact
Subscribe
Paywall Login
Login to Comment
Register
December 11th, 2017
jobs
homes
Menu
Home
News
Sports
Business
Entertainment
Classifieds
Commentary
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Novo Nordisk A/S Common Stock
(NY:
NVO
)
48.45
-0.78 (-1.58%)
Official Closing Price
Updated: 7:00 PM EST, Feb 19, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
8,289,445
Open
48.72
Bid (Size)
48.36 (200)
Ask (Size)
48.49 (200)
Prev. Close
49.23
Today's Range
48.18 - 48.77
52wk Range
43.08 - 93.80
Shares Outstanding
N/A
Dividend Yield
2.41%
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street
↗
February 19, 2026
These biotech companies have catalysts ahead.
Via
The Motley Fool
Warning: This Skyrocketing Stock Has a Hidden Risk
↗
February 19, 2026
Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.
Via
The Motley Fool
Topics
Intellectual Property
Performance
YTD
-7.5%
-7.5%
1 Month
-20.2%
-20.2%
3 Month
+1.8%
+1.8%
6 Month
-12.6%
-12.6%
1 Year
-41.9%
-41.9%
More News
Read More
Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention
↗
February 19, 2026
Via
The Motley Fool
Novo Looks To Ireland To Scale Production Of Wegovy Pill: Report
↗
February 12, 2026
Via
Stocktwits
HIMS Stock Plunges 8 Straight Days: Is The GLP-1 Fallout Already Priced In?
↗
February 11, 2026
Via
Stocktwits
Hims & Hers HUGE Acquisition News!
↗
February 19, 2026
Via
The Motley Fool
Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush
↗
February 19, 2026
Via
The Motley Fool
The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth
February 17, 2026
Via
MarketMinute
Topics
Earnings
Economy
NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection
↗
February 17, 2026
Via
Stocktwits
Topics
Lawsuit
2026 Could Be a Big Year for Viking Therapeutics. Time to Buy?
↗
February 17, 2026
Via
The Motley Fool
Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy?
↗
February 16, 2026
Via
The Motley Fool
Got $500? 2 Pharma Stocks to Buy and Hold Forever.
↗
February 14, 2026
Via
The Motley Fool
Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar
↗
February 13, 2026
Via
Stocktwits
Topics
Lawsuit
Meet the 6.3% Yield Dividend Stock That Could Soar in 2026
↗
February 13, 2026
Via
The Motley Fool
Topics
Intellectual Property
VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout?
↗
February 12, 2026
Via
Stocktwits
Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know.
↗
February 12, 2026
Via
The Motley Fool
Novo Nordisk CEO Sees Opportunity For 15 Million New Patients As Medicare Covers Obesity Drugs
↗
February 12, 2026
Via
Benzinga
Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly
↗
February 11, 2026
Via
Stocktwits
Topics
Intellectual Property
The Greenland Gambit: Inside the Transatlantic Tariff Shock and the Future of Arctic Sovereignty
February 11, 2026
Via
MarketMinute
Topics
Bonds
Economy
Government
Disney Has Its Next CEO
↗
February 11, 2026
Via
The Motley Fool
Healthcare Stocks Are Sinking. Here Are 2 to Buy on the Dip.
↗
February 11, 2026
Via
The Motley Fool
Biotech Beat Nvidia in 2025. Can It Do It Again?
↗
February 11, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
↗
February 11, 2026
Via
The Motley Fool
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know
↗
February 10, 2026
Via
The Motley Fool
AstraZeneca Signals a New Era in Obesity Care: Earnings Report Teases Oral GLP-1 Powerhouse
February 10, 2026
Via
MarketMinute
Topics
Artificial Intelligence
Earnings
Economy
Frequently Asked Questions
Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 48.45
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 02/19/26 07:00 PM ET
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.